Skip to main content
Industry News
Sublingual immunotherapy may benefit youths with peanut allergy

Sixty-seven percent and 25% of 48 children with peanut allergy ages 1 to 11 who received sublingual immunotherapy ate at least 750 mg and 5,000 mg of peanut protein without developing clinical symptoms, respectively, researchers reported in The Journal of Allergy and Clinical Immunology. The findings also showed that transient oropharyngeal itching was the most prevalent side effect of SLIT, but only few side effects required antihistamine treatment.

Full Story: